Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9147–9152 | Cite as

The emerging role of Nemo-like kinase (NLK) in the regulation of cancers

Review

Abstract

Nemo-like kinase (NLK) is an evolutionarily conserved mitogen-activated protein (MAP) kinase-related kinase that is highly expressed in neural tissues and minimally detected in others. Accumulating evidence demonstrates that NLK exerts a pivotal role in cell proliferation, migration, invasion, and apoptosis via regulation of a variety of transcriptional molecules. The results of recent studies have shown that aberrant expression of NLK is significantly associated with the initiation and progression of various types of human cancers, as well as clinicopathologic features and survival rate. NLK is gradually considered as a potential tumor suppressor or an oncogene depending on the tumor system, and silencing or upregulating of NLK may provide an effective therapeutic approach against tumors. In this review, we will make a summary on the comprehensive roles of NLK in the regulation of various cancers.

Keywords

Nemo-like kinase Wnt Non-coding RNA Cancer 

Notes

Acknowledgments

This project was supported by the National Science Foundation of China (grant nos. 81473268 and 81273526).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Choi KW. Rotation of photoreceptor clusters in the developing Drosophila eye requires the nemo gene. Cell. 1994;78:125–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Brott BK. Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci U S A. 1998;95:963–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Katoh M. Comparative genomics on nemo-like kinase gene. Int J Oncol. 2005;26:1715–9.PubMedGoogle Scholar
  4. 4.
    Kortenjann M. Abnormal bone marrow stroma in mice deficient for nemo-like kinase Nlk. Eur J Immunol. 2001;31:3580–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Ishitani T. Nemo-like kinase is involved in NGF-induced neurite outgrowth via phosphorylating MAP1B and paxillin. J Neurochem. 2009;111:1104–18.CrossRefPubMedGoogle Scholar
  6. 6.
    Xu D. Expression of Nemo-like kinase after spinal cord injury in rats. J Mol Neurosci. 2014;52:410–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ota S. NLK positively regulates Wnt/beta-catenin signalling by phosphorylating LEF1 in neural progenitor cells. EMBO J. 2012;31:1904–15.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Thorpe CJ. nemo-like kinase is an essential co-activator of Wnt signaling during early zebrafish development. Development. 2004;131:2899–909.CrossRefPubMedGoogle Scholar
  9. 9.
    Ishitani T. Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal. 2013;25:190–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Jung KH. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 2010;110:687–96.CrossRefPubMedGoogle Scholar
  11. 11.
    Li M. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol. 2013;34:3995–4000.CrossRefPubMedGoogle Scholar
  12. 12.
    Emami KH. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate. 2009;69:1481–92.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhang Y. Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer. 2011;21:1380–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Huang Y. Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PLoS One. 2013;8:e69148.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shaw-Hallgren G. Association of nuclear-localized Nemo-like kinase with heat-shock protein 27 inhibits apoptosis in human breast cancer cells. PLoS One. 2014;9:e96506.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lv L. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J Cell Biochem. 2014;115:81–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Cui G. Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci. 2011;18:271–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Han Y. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother. 2014.Google Scholar
  19. 19.
    Chen J. Nemo-like kinase expression predicts poor survival in colorectal cancer. Mol Med Rep. 2015;11:1181–7.PubMedGoogle Scholar
  20. 20.
    Tan Z. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol Cell Biochem. 2012;369:27–33.CrossRefPubMedGoogle Scholar
  21. 21.
    Yasuda J. Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem Biophys Res Commun. 2003;308:227–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Dong JR. Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer. Asian Pac J Cancer Prev. 2013;14:7137–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Kohlhapp FJ. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015.Google Scholar
  24. 24.
    Song JL. microRNA regulation of Wnt signaling pathways in development and disease. Cell Signal. 2015;27:1380–91.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chen Z. The pivotal role of microRNA-155 in the control of cancer. J Cell Physiol. 2014;229:545–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Ji J. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–80.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Wang K. miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol. 2013;15:578–88.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shen Q. MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer. Cancer Lett. 2014;344:204–11.CrossRefPubMedGoogle Scholar
  29. 29.
    Zou D. MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK. Tumour Biol. 2015.Google Scholar
  30. 30.
    Xu ZY. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer. Int J Biol Sci. 2013;9:587–97.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yang F. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol. 2013;139:437–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Vernucci M. The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene. 2000;19:6376–85.CrossRefPubMedGoogle Scholar
  33. 33.
    Du Y. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem. 2012;287:26302–11.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hajjari M. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12:1–9.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Martens-Uzunova ES. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65:1140–51.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang JX. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro Oncol. 2013;15:1595–603.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zhou X. HOTAIR is a therapeutic target in glioblastoma. Oncotarget. 2015.Google Scholar
  38. 38.
    Takebe N. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97–106.CrossRefPubMedGoogle Scholar
  39. 39.
    Gatcliffe TA. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer. 2008;18:954–62.CrossRefPubMedGoogle Scholar
  40. 40.
    Ishitani T. Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol. 2003;23:1379–89.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yasuda J. Mammalian Nemo-like kinase enhances beta-catenin-TCF transcription activity in human osteosarcoma and neuroblastoma cells. Proc Jpn Acad Ser B Phys Biol Sci. 2007;83:16–25.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Quinn DI. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858–87.CrossRefPubMedGoogle Scholar
  43. 43.
    Bender TP. Critical functions for c-Myb at three checkpoints during thymocyte development. Nat Immunol. 2004;5:721–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural ProductsAnhui Medical UniversityHefeiChina
  2. 2.The Key Laboratory of Anti-inflammatory and Immune Medicine, Anhui Medical UniversityMinistry of EducationHefeiChina
  3. 3.Department of CardiologyThe First Affiliated Hospital of Anhui Medical UniversityHefeiChina

Personalised recommendations